NEW
YORK, Oct. 5, 2022 /PRNewswire/ -- AIkido Pharma
Inc. (NASDAQ: AIKI) ("AIkido" or the "Company") today provided an
update on the Company's share repurchase program (the "Share
Repurchase Program") authorized by the Company's Board of Directors
on January 21, 2022.
The Company reported that on October 4,
2022, the Company purchased 38,035 shares of common stock at
$6.99 per share. Anthony Hayes, CEO of AIkido stated, "We believe the Company stock
continues to be undervalued and we are using this opportunity to
enhance shareholder value by reducing the amount of stock that is
outstanding."
Additional shares may be repurchased from time to time in open
market transactions, or other means in accordance with Rule 10b5-1
of the Securities Exchange Act of 1934, as amended (the "Exchange
Act"), and Rule 10b -18 of the
Exchange Act. The timing, number of shares repurchased, and prices
paid for the stock under this program will depend on general
business and market conditions as well as corporate and regulatory
limitations, including blackout period restrictions.
About AIkido Pharma Inc.
AIkido Pharma Inc. was initially formed in 1967 and is a
biotechnology Company with a diverse portfolio of small-molecule
anticancer and antiviral therapeutics. The Company's platform
consists of patented technology from leading universities and
researchers, and we are currently in the process of developing an
innovative therapeutic drug platform through strong partnerships
with world renowned educational institutions, including The
University of Texas at Austin and
University of Maryland at Baltimore.
Our diverse pipeline of therapeutics includes therapies for
pancreatic cancer, prostate cancer. We are constantly seeking to
grow our pipeline to treat unmet medical needs in oncology. The
Company is also developing a broad-spectrum antiviral platform that
may potentially inhibit replication of multiple viruses including
Influenza virus, SARS-CoV (coronavirus), MERS-CoV, Ebolavirus and
Marburg virus.
Forward-Looking
Statements
Certain statements in this press release constitute
"forward-looking statements" within the meaning of the federal
securities laws. Words such as "may," "might," "will," "should,"
"believe," "expect," "anticipate," "estimate," "continue,"
"predict," "forecast," "project," "plan," "intend" or similar
expressions, or statements regarding intent, belief, or current
expectations, are forward-looking statements. While the Company
believes these forward-looking statements are reasonable, undue
reliance should not be placed on any such forward-looking
statements, which are based on information available to us on the
date of this release. These forward-looking statements are based
upon current estimates and assumptions and are subject to various
risks and uncertainties, including without limitation those set
forth in the Company's filings with the SEC, not limited to Risk
Factors relating to its business contained therein. Thus, actual
results could be materially different. The Company expressly
disclaims any obligation to update or alter statements whether as a
result of new information, future events or otherwise, except as
required by law.
Contact:
Investor Relations:
Hayden IR
Brett Maas, Managing Partner
Phone: (646) 536-7331
Email: brett@haydenir.com
www.haydenir.com
AIkido Pharma Inc.:
Phone: 212-745-1373
Email: investorrelations@aikidopharma.com
www.aikidopharma.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/aikido-purchases-more-shares-301641536.html
SOURCE AIkido Pharma Inc.